Epithelial-mesenchymal transition (EMT) is a crucial step in tumor metastasis. Triple negative (TN) breast cancer, a high metastasis phenotype, has been verified to be associated with EMT. Melanoma associated antigen-A (MAGE-A) is exclusively expressed in cancers with high aggressiveness as well as unfavorable prognosis and likely to be associated with EMT of triple negative breast cancer (TNBC). The aim of the study is to analyze the expression profile of MAGE-A in breast cancer and the correlation between MAGE-A and EMT of TNBC. Immunohistochemistry (IHC) was performed to assess the prevalence of MAGE-A, vimentin, E-cadherin and β-catenin in breast cancer tissues and correlate them with clinical pathological parameters. The association between MAGE-A and EMT markers was also evaluated. Scratch assay and transwell invasion assay were carried out to evaluate the impact of MAGE-A down-regulation on migration and invasion of the breast cancer cells. Real-time PCR was also conducted to evaluate alterations in EMT markers with decrease in MAGE-A. The results showed that MAGE-A was absent in normal tissue but expressed in tumor samples with the incidence of 49.17% (P=0.008). MAGE-A staining was higher in TNBC (76.47%, 13/17), followed by HER-2(+) (53.85%, 7/13) and Luminal set (43.33%, 39/90), and it was significantly correlated with ER (-), PR (-), HER-2 (-), lymph nodes involvement and higher histological grade (P<0.05). E-cadherin-positivity was frequent in Luminal set (94.44%, 85/90) and linked to ER (+), negative lymph nodes and lower histological grade (P<0.05). Vimentin expression was often observed in TNBC (70.59%, 12/17) and ER (-), PR (-), lymph nodes (+) groups (P<0.05). Expression of β-catenin was prevalent in Luminal set (93.33%, 84/90) and correlated with ER (+), PR (+) and lower histological grade (P<0.05). MAGE-A was inversely associated with E-cadherin (P=0.011) and β-catenin (P=0.048) but expressed in the same trend with vimentin (P=0.000). Migration and invasion of MDA-MB-231 were inhibited when MAGE-A decreased. Increase in epithelial markers and decline in mesenchymal indicators were also seen with MAGE-A reduction. Snail, Slug, ZEB1 and ZEB2 were also down-regulated. In conclusion, MAGE-A may be responsible for high aggressiveness and EMT of TNBC and can be a new choice for targeted therapy.
vimentin, N-cadherin and matrix metalloproteinases (MMPs) [7] . This process is regulated by several transcription regulators including Snail (Snail1 and Snail2), Zinc Finger E-box Binding Homeobox 1 (ZEB1) and 2 (ZEB2) and basic helix-loop-helix (bHLH) (E47 and Twist) families [8] . EMT has been accepted as a contributor to tumor progression, metastasis and drug resistance [9] [10] . What's more, it has been proved that EMT is highly linked to aggressiveness of TNBC [11] [12] [13] [14] .
Cancer/testis antigens (CTA), a series of tumor associated antigens, are exclusively expressed in diverse tumor entities [15] but silent in normal tissues except for testicular germ cells and placenta [16] [17] [18] . Due to the restricted expression pattern and their capability to elicit immune responses, CTAs are counted as ideal targets for immunotherapy in human malignancy [19] [20] . Melanoma associated antigen (MAGE), a member of CTA, is composed of type I (MAGE-A, MAGE-B, and MAGE-C) and type II (MAGE-D) family based on variation in gene structure and tissue-specific expression pattern [21] . MAGE-A consists of 12 homologous genes (MAGE-A1 to -A12) located in the q28 region of chromosome X [21] . Accumulating evidence showed that MAGE-A expression is accused for tumor growth and progress [23] [24] [25] [26] . Moreover, MAGE-A expression is detected frequently in TNBC patients [27] .
Above all, we speculate that MAGE-A may contribute to EMT of TNBC. In order to address this issue, immunohistochemistry (IHC) was performed to investigate the expression pattern of MAGE-A and EMT markers (vimentin, E-cadherin, β-catenin) in breast cancer tissues and correlate them with clinicopathologic parameters. Also, we evaluated the association between MAGE-A and EMT markers. Then, MAGE-A expression was knocked down to detect its influence on invasive and migratory potential and alterations in EMT markers of triple-negative breast cancer cell line MDA-MB-231, known to be highly metastatic. The results showed that MAGE-A expression was more prevalent in TNBC patients and associated with indicators suggestive of unfavorable prognosis. Furthermore, MAGE-A could regulate EMT of MDA-MB-231 partially.
Patients and methods
Patients and samples. Samples including 120 cancer tissues and 10 tumor-free tissues were obtained from a consecutive series of 120 female breast cancer patients who underwent mastectomy at the Center of Breast Cancer of The Fourth Hospital of Hebei Medical University (Shijiazhuang Hebei), over a six-month period (2013.9-2014.2). All cases were diagnosed with breast cancer via needle biopsies examination. None of them obtained chemotherapy and radiotherapy before operation. Postoperative pathological examination of primary resected tumors was performed at Department of Pathology of that hospital. The clinicopathological indexes were collected including: age, menstrual status, histological type and grade, tumor size, lymphatic metastasis, blood vessel invasion, TNM stage, ER, PR, Topoisomerase II (TOPOII), Ki-67, p53 and HER-2. All patients provided written informed consent before enrollment. The study was approved by the Medical Ethics Committee of the Fourth Hospital of Hebei Medical University.
Cell lines and transfection. Triple negative breast cancer cell line MDA-MB-231, obtained from Research Cancer of the Forth Hospital of Hebei Medical University, was cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum, penicillin (100 U/ml), and streptomycin (100 μg/ml) at 37°C in 5% CO 2 . MAGE-A siRNA (h) (SC-35843, SANTA CRUZ BIOTECHNOLOGy, USA), a pool of 6 different siRNA duplexes, was transiently transfected into MDA-MB-231 cells using FuGENE HD (E2311, Promega USA). MAGE-A siRNA (h) sequence was as follows: sense: 5'-AGUCACACAUAGUGCUGUUTT-3', antisense: 5'-AACAGCACUAUGUGUGACUT T-3'; sense:5'-AGAGGGAGUCUGAGCAUGAT T-3', ant i s e n s e : 5 ' -U C AU G C U C AG AC U C C C U C U T T-3 ' ; sense: 5'-CUACCCAUCCCUUUAUGAAT T-3', ant i s e n s e : 5 ' -U U C AUA A AG G G AU G G G UAG T T-3 ' ; sense:5'-GGAAGCACUUGAUGAGAAAT T-3', ant i s e ns e : 5 ' -U U U C U C AU C A AG U G C U U C C T T-3 ' ; sense: 5'-CCCAAGAUAUACUACAUGATT-3', antisense: 5'-UCAUGUAGUAUAUCUUGGGTT-3'; sense:
Immunohistochemistry. Briefly, paraffin-embedded tissues were cut as 4μm sections and then deparaffinized, rehydrated and incubated in EDTA (Ethylene Diamine Tetraacetic Acid, pH 9.0) at 100°C for 4 minutes. Next, the sections were stained with MAGE-A primary antibody (6C1 mAb, 1:50, Santa Cruz Biotechnology, USA) which can react with MAGE-A1, 2, 3, 4, 6, 12, vimentin antibody (1:500, Santa Cruz Biotechnology, USA), E-cadherin (1:250, Biosynthesis, China), β-catenin (1:250, Biosynthesis, China) and corresponding secondary antibody. Visualization was done after incubation with DAB (3, 3'-Diaminobenzidine Tetrahydrochlorid, ZSGB-BIO, China). Testis tissue was used as the positive control, tumor-free breast tissue was stained as negative control. Figures were taken in 200× and 400× magnifications to document the positively stained areas. All samples were evaluated by two observers.
Scoring. MAGE-A: The detection of nuclear and /or cytoplasmic staining in any percentage of tumor cells was considered positive for MAGE-A. Complete absence of staining was considered negative for MAGE-A expression [28] .
E-cadherin, β-catenin: Expression was scored by assessing the stain intensity and the percentage of stained cells in the tumors. Staining intensity was scored as 0 (no staining), 1+ (weak), 2+ (medium), or 3+ (strong). The percentage of stained cells was classified as follows: 1, 0% to 10% stained cells; 2, 11% to 50% stained cells; 3, 50% stained cells or greater. The final score was obtained by multiplying the two scores. Cases with a score of 0 to 4 were interpreted as (-), and those with a final score of 5 to 9 were classified as (+) [29] .
Vimentin: Any distinct positive staining of the tumor cell cytoplasm with the vimentin antibody was considered as positive vimentin expression [30] .
RNA extractions and RT-PCR. Total RNA of cultured cells was isolated using the TRNzol Reagent (DP405-02, TIANGEN, China). The RNA concentration was routinely measured and its quality was determined by agarose gel electrophoresis stained with GoTaq Green Master Mix (A5001, Promega, USA). RNA was reverse transcribed to cDNA using RevertAid First Strand cDNA Synthesis Kit (A5000, Promega, USA). For RT-PCR, the primers were designed as Table 1 . GAPDH was used as reference gene and its sequence was listed in Table 1 . The amplification conditions were: pre-degeneration at 95°C for 5 min followed by 35 cycles of degeneration at 95°C for 30 sec, annealing for 30 sec at various temperatures depending on the targeted genes and extension at 72°C for 30 sec followed by the final extension at 72°C for 7min. PCR products were confirmed by agarose gel electrophoresis. The bands were visualized and analyzed by GBOXEF2 GENESys (Syngene Image Software, Cambridge, UK).
Real-time qRT-PCR. Briefly, total RNA was extracted from cells, and cDNA was reverse-transcribed using GoScript TM Reverse Transcription System (A5000, Promega, USA). Quantitative real-time RT-PCR (qRT-PCR) was carried out in quadruplicate using GoTaq qPCR Master Mix (A6002, Promega, USA) via 7500 FAST Real-Time PCR system (Applied Biosystems, USA). PCR was performed using the following primers displayed in Table 1 . Samples underwent three-step amplification for 35 cycles: denaturation at 95°C for 30sec, the annealing temperature depending on different primers listed in the table for 30 sec, and extension at 72°C for 30 sec. The CT values for the tested genes were normalized to GAPDH and relative expression represented as 2 −ΔΔCT . Scratch assay. 5.0 × 10 5 cells were evenly seeded in 6-well plates per well and incubated until they reached confluency. After transfection with siRNA for 24h, confluent cell layers were washed with PBS then scratched perpendicularly with a sterile 200μl pipette tip to generate homogeneous wounds in each well. After washing with PBS, the cells were incubated with non-serum medium for another 24 h. The changes of the migratory distance were observed and the images were taken via microscope at 100× magnifications (TE2000-U; Nikon, Japan). The movement distance of the cells across the wound was measured using NIS-Elements F 2.30 (Nikon, Japan). The results were represented as relative migration rate (%). The experiment was repeated for six times.
Transwell invasion assay. After siRNA transfection for 24h, 1×10
5 cells in serum-free medium were seed in the upper chamber on the 8.0 μm porous polycarbonate membrane (Coring Incorporated Costar, 3422, USA) coated with Matrigel (BD354248, BD, USA). The lower chamber was filled with medium containing 10% fetal bovine serum. After 24 h incubation, the cells from the upper surface of the fil ter were removed with cotton tips, and the cells that invaded to the underside of the filter were fixed in 4% paraform and stained with crystal violet. Images were captured by microscope (TE2000-U; Nikon, Japan) at 200 × magnification. Cells in 10 random microscopic fields were counted and presented as the average number of cells / field of view.
Statistics. Statistical analyses were performed using statistical software of SPSS 16.0 (Inc.; Chicago, USA). The positive rate of MAGE-A and EMT markers, and the association between them and clinical pathological indicators were analyzed by Pearson's χ2 test or Continuity Corrected Pearson's χ2 test or Fisher's exact test. The Student's t test was used to compare differences between groups concerning parametric variables. P-value <0.05 was considered statistically significant.
Results
Clinico-pathological characteristics. The clinicopathological characteristics of the subjects are listed in Table 3 . All cases in this study were female aged from 28 to 83 years. 59 out of all cases were premenopausal whereas 61 patients were postmenopausal. The tumor size of 64 patients were ≤ 2 cm, while others were larger than 2cm. Positive axillary lymph nodes were found in 68 cases, whereas 42 patients were found to be negative. Figure 1 , MAGE-A gene expression was observed in cytoplasm and/ or nucleus of cancer cells. About 49.17% (59/120) of all cases were MAGE-A-positive, while none of the tumor-free samples was stained with MAGE-A antibody (P=0.008) (Figure 2 ). MAGE-A was positively expressed in normal testis tissues as documented in Figure 3 . As for breast cancer subtypes, MAGE-A staining was observed in 39 cases (43.33%, 39/90) belonging to Luminal set. The prevalence of MAGE-A in HER-2(+) and TN set were 53.85% (7/13) and 76.47% (13/17), respectively. The difference of MAGE-A positivity among the subgroups was significant (P=0.041) ( Table 2) . Representative positive staining case of each set was shown in Figure 1 . HER-2(+) set (×200, ×400) G. Negative expression of MAGE-A in TN set (×200) H, I. MAGE-A staining in TN set (×200, ×400) . MAGE-A expression was concerned with tumor aggressiveness and metastasis. To assess the role of MAGE-A in breast cancer pathogenesis, we investigated the distribution of MAGE-A in different pathological indexes of the patients. As shown in Table 3 , MAGE-A was significantly associated with ER (-) (P=0.027), PR (-) (P=0.000) and HER-2 (-) (P=0.017), and this might be a reason for the high incidence of MAGE-A in TN subset. MAGE-A was more prevalent in patients with higher histological grade (grade II and III) (P=0.001) and axillary lymphatic metastasis cases (P=0.000) indicating that MAGE-A is highly responsible for cancer metastasis and aggressiveness. There was no correlation was established between MAGE-A expression and other parameters (P>0.05). Accordingly, MAGE-A has link with indicators predicting bad outcomes, and it is exactly responsible for aggressiveness of malignant phenotypes.
Decrease in epithelial markers and elevation in mesenchymal markers were observed in TNBC. To assess the expression profile of EMT markers in different breast cancer subtypes, IHC was performed to analyze vimentin, E-cadherin and β-catenin expression in subjected cancerous cases ( Table 2) . We observed that vimentin was expressed in cytoplasm. It was positive in 41 (41/120) of all cases with the highest prevalence in TN set (12/17, 70.59%) followed by HER-2 overexpression (6/13, 46.15%) and Luminal set (23/90, 25.55%), and the difference among the subtypes was statistically significant (P=0.001). The staining of E-cadherin could be seen in membranous or cytoplasm in 105 samples (105/120, 87.50%). Cases from Luminal set were more prone to be positive with E-cadherin (85/90, 94.44%), while patients in HER-2 overexpression (11/13, 84.61%) and TN group (9/17, 52.94%) were less in E-cadherin positivity (P=0.000). β-catenin expression was mainly observed in cytoplasm and nucleus. It was expressed in 98 patients of all (98/120, 81.67%), showing the higher positive rate in Luminal set (84/90, 93.33%) but less in HER-2 (+) set (7/13, 53.85%) and TNBC (7/17, 41.18%) (P=0.000). It was obvious that lower expression of epithelial markers and higher level of mesenchymal markers were frequently seen in TN-type predicting the existence of EMT in TNBC. Representative staining cases of EMT markers were shown in Figure 4 .
Loss of epithelial markers and gain of mesenchymal markers indicated high tendency to metastasis and bad prognosis. To further our study in association between EMT and breast cancer subtypes, we analyzed the distribution of the EMT markers in related pathological indexes of patients. As shown in Table 3 , E-cadherin was inversely linked to ER (-) (P=0.000), positive lymph nodes (P=0.012) and high histological grade (P=0.009). Similarly, β-catenin expression was significantly related to ER-positive (P=0.000), PR-positive (P=0.011) and low histological grade (P=0.000). Instead, vimentin expression was more frequent in ER (-) (P=0.001), PR (-) (P=0.000), lymph nodes (+) cases (P=0.009). There was no correlation established between EMT markers and other pathological parameters (P>0.05). As such, the loss of epithelial markers and acquisition of mesenchymal markers demonstrated high tendency to metastasis and bad prognosis. Evidently, EMT is more prone to occur in TNBC characteristic with ER (-), PR (-) and HER-2 (-). MAGE-A positive cases were more likely to undergo EMT. Since EMT and high expression of MAGE-A are all responsible for high aggressiveness of malignancies, we raise the hypothesis that MAGE-A may be linked to EMT. To test our assumption, we analyzed the relationship between MAGE-A and EMT markers. The results were documented in Table 4 . As expected, MAGE-A was significantly associated with vimentin-positive (P=0.000), but inversely correlated with Ecadherin-positive (P=0.011) as well as β-catenin-positive cases (P=0.048). The results demonstrated that MAGE-A positive cases were more inclined to undergo EMT.
Suppression of MAGE-A inhibited metastasis of MDA-MB-231 cells. MAGE-A was down-regulated in highly metastatic phenotype breast cancer cell line-MDA-MB-231 via siRNA transfection to gain insight into the roles of MAGE-A in breast cancer metastasis. MAGE-A1, 2, 3, 4, 6, 12 were all knocked down in varying degrees confirmed by RT-PCR analyses ( Figure 5 ). We observed that MAGE-A downregulation did not transform the spindle-like morphology of MDA-MB-231 cells to obvious epithelioid structure. However, the migratory and invasive capabilities of MAGE-A depletion cells were remarkably reduced as compared with the control cells ( Figure 6, 7) . Hence, MAGE-A expression was predictive of high potential to metastasis in aggressive breast cancer phenotypes. Decrease in MAGE-A raised E-cadherin and β-catenin and reduced vimentin and N-cadherin. Based on the correlation between MAGE-A expression and metastasis of breast cancer as well as the crucial role of EMT in cancer metastasis, we assessed the expression of epithelial and mesenchymal markers in MDA-MB-231 using real-time PCR. Intriguingly, the epithelial markers E-cadherin and β-catenin were evidently enhanced with a concomitant decrease in mesenchymal markers vimentin and N-cadherin (Figure 8 ). Since decline in epithelial markers and elevation in mesenchymal markers are hallmarks of EMT, we concluded that MAGE-A expression may partially regulate EMT of MDA-MB-231. During EMT, MMPs are activated leading to extracellular matrix degradation and tumor cells metastasis. Our data showed that MMP9 remarkably decreased with MAGE-A down-regulation confirming the inhibition of metastasis caused by reduced MAGE-A expression (Figure 8) .
MAGE-A regulated the expression of transcription factors in EMT. Snail, Slug, ZEB1 and ZEB2 are well-known transcriptional factors of EMT. When EMT occurs, they will be activated and repress the promoter activation of E-cadherin. In order to investigate the impact of MAGE-A on EMT, expression profile of Snail, Slug, ZEB1 and ZEB2 were also analyzed. As shown in Figure 9 , expression of the transcriptional factors were significantly down-regulated in MAGE-A loss group relative to the control cells, which suggested that MAGE-A could control EMT in part via regulation of transcriptional factors activated during EMT in MDA-MB-231.
Discussion
Due to lacking of effective treatment target and high aggressiveness, it is urgent to research on the mechanism of metastasis and explore new oncogenes responsible for invasion of TNBC. EMT has been recognized as the key for cancer metastasis, thus, it is essential to correlate oncogenes with EMT and provide basis for new therapeutic options. MAGE-A is a member of CTAs characteristic with restricted expression in germline cells and aberrant expression in a variety of cancers of disparate origins [18] [19] . It is often coordinated [33] and related to aggressive cancer types [34] [35] and poor clinical prognosis [36] . To this end, we put forward that MAGE-A may be an important contributor to EMT of TNBC.
We firstly analyzed the expression pattern of MAGE-A in 120 breast cancer cases and 10 tumor-free samples. The results showed that MAGE-A was specifically expressed in neoplastic samples with a percentage of 49.17%. Chen et al [37] showed 17% of MAGE-A-positive cases and Kavalar et al [38] observed 64.2% of MAGE-A -expressed cases. The differences may be due to the diverse primary antibodies and scoring methods we used. We also analyzed the expression of MAGE-A in different subtypes. As expected, cases from TN group accounting for the highest proportion of MAGE-A bearing cases (76.47%), followed by HER-2 enriched set (53.85%) and Luminal set (43.33%). A series of studies have been committed to evaluate MAGE-A expression in breast cancer cases with specific biomarkers. Curigliano et al [27] assessed expression of MAGE-A in 50 ER (+) /HER-2 (-) and 50 TN cases by IHC method. They found 32% TN cases with higher intensity of MAGE-A, while 18% ER (+) cases were positive for MAGE-A with lower intensity. According to Chen et al [45] , the frequency of MAGE-A in ER-negative set was 24.5% which was higher compared to ER (+) cases. The specific expression pattern of MAGE-A in different breast cancer subtypes make it another biomarker for breast cancer classification. Moreover, the relative high prevalence of MAGE-A is believed to be another reason for aggressiveness of TNBC.
Then, we correlated MAGE-A with clinical pathological indicators. We showed that MAGE-A was markedly associated with ER (-), PR (-), and HER-2 (-), which demonstrated that MAGE-A expression is actually associated with TN set further. Also, MAGE-A-positive cases were often with high histological grade and metastatic axillary lymph nodes, which strengthened the association between MAGE-A and cancer progression. According to some studies, MAGE-A proteins have to do with negative hormone receptor status, high histologic grade [37, 39] , large tumor size (≥2cm) [36] , positive sentinel lymph nodes (SLN) [40] , high Ki-67 score [27] and HER-2 negativity. Notably, MAGE-A expression is contributed to unfavorable outcomes and cancer development.
EMT is a key mechanism for the metastasis of malignant tumors [41] [42] [43] [44] . Down-regulation of epithelial markers and elevation in mesenchymal markers are hallmarks of EMT [45] [46] [47] [48] [49] . In this study, we analyzed the expression of well-known EMT markers in breast cancers and related them to pathological indexes. We concluded that vimentin was more frequent in TNBC compared to E-cadherin and β-catenin which were prevalent in Luminal set. In Hoiseon's [50] study, 25.4% of TN-type patients were vimentin-positive, and decreased Ecadherin expression was seen in 16.7% TNBC. However, the corresponding data was 4.1% and 11.8% in hormone receptorpositive cases, respectively. Nami et al [11] reported that the expression of vimentin was significantly higher in TN cases relative to other subtypes immunohistochemically. Seema et al [29] found E-cadherin was predominantly positive in non-TNBC, whereas significant increased expression of vimentin was observed in TN cases. Our result was in accordance with the data listed above, which indicated that EMT is certainly a common phenomenon in TNBC. We also assessed relationship between EMT markers and pathological indexes. We found that vimentin expression was associated with ER (-) PR (-) lymph nodes (+) cases, whereas E-cadherin was inversely linked to ER (-), positive lymph nodes and high histological grade. Moreover, β-catenin was significantly related to ER (+), PR (+) and lower histological grade. A battery of studies uncovering the similar results [11, 50] implied the actual association between EMT and TNBC.
We also found that MAGE-A was significantly associated with vimentin (+) and E-cadherin /β-catenin (-) cases, which suggested that MAGE-A may be correlated with EMT. Accordingly, in view of the crucial role of EMT in cancer metastasis, we assumed that MAGE-A is more likely to be responsible for EMT of TNBC. According to our results, decreased MAGE-A significantly inhibited migration and invasion of MDA-MB-231 and led to increase in epithelial markers and down-regulation of mesenchymal markers. As we all know EMT is marked by loss of epithelial markers and enhancement in mesenchymal indicators. The results we obtained demonstrated that MAGE-A down-regulation may reverse EMT of MDA-MB-231 cell line. The conclusion was further verified by the decreased transcriptional factors activated during EMT in the context of MAGE-A downregulation. Though no significant changes in morphology of MDA-MB-231, these results informed us that MAGE-A can regulate EMT of TNBC in part. Degradation of extra cellular matrix by MMPs is the key for cancer metastasis. When EMT occurs, MMPs are activated to facilitate degradation of extra cellular matrix. In this study we observed that MAGE-A downregulation resulted in MMP9 reduction indicating the positive role of MAGE-A in cancer metastasis. In consequence, high level of MAGE-A is another reason for high metastasis and bad prognosis of TNBC. To our knowledge, we provide the first evidence that MAGE-A expression is correlated with EMT in TNBC providing a new clue for therapeutic options. By far, no study refers to association between MAGE-A members and EMT in cancers. However, expression of MAGE-C2 was clarified to be responsible for breast cancer metastasis and was able to induce EMT in breast cancer cell lines [51] . The mechanism underlying the event was not elucidated yet. Nevertheless, concerning the positive function of MAGE-A in breast cancer progression, it is reasonable to believe that MAGE-A is a pivotal contributor to EMT of TNBC.
Conclusions
In conclusion, we showed that MAGE-A is highly expressed in TNBC and associated with factors predicating highly metastasis. What's more, MAGE-A has an impact on TNBC progression via the regulation of EMT. Together, these conclusions provide a new clue for EMT-related oncogene and yield new insight into cancer metastasis and novel avenues for treatment. Further studies should be done to explore the exact mechanism and signals involved in MAGE-A related EMT.
